LONDON, August 24, 2012 /PRNewswire/ --
Pharma IQ has just published the results of an industry wide clinical trials survey, conducted recently among 4,500 clinical specialists with over 40% located in Europe.
Over a third of the clinical trial supply respondents to our recent survey said that outsourcing distribution and logistics was their main priority for the investment this year, whereas cool chain technologies was mentioned by 27%. Quarter of the respondents will focus on the supply chains in emerging markets. Other concerns included IVRS technology, labelling technologies and outsourcing. Added to this, the number of clinical trials to be conducted in the BRIC region in 2013 is predicted to increase to 70.7%.
Pharma IQ also asked the respondents about the top areas for improvement in the clinical trial supply. Understanding GDP regulations and designing a supply chain for adaptive clinical trials were the most common issues closely followed by a just-in-time labelling strategy and computer sourcing.
The infographic is available to download at http://www.clinicalsupplyeurope.com/news.
The survey was created as a part of the pre-conference research for Clinical Trial Supply, taking place 30 January-01 February 2013.
The results helped to shape the CTS Online Library consisting of regularly updated presentations, speaker Interviews and presentations coordinated with the IQPC clinical trials event.
0ther content available in CTS Online Library includes:
- Interview with Robert Smith, former Director, Clinical Pharmacy Research Services at Genzyme. Mr Smith discusses the latest approaches and tools to ensure flexibility of clinical supplies. He talks about the use of IRT, removing expiry dates and pooling supplies all with a view to reducing waste and making efficiency improvements. There is also an overview of the role of BRIC countries in the n
|SOURCE Pharma IQ|
Copyright©2012 PR Newswire.
All rights reserved